SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0000950142-22-000407
Filing Date
2022-01-21
Accepted
2022-01-21 13:07:32
Documents
3
Group Members
GAP (BERMUDA) L.P.GAP COINVESTMENTS CDA, L.P.GAP COINVESTMENTS III, LLCGAP COINVESTMENTS IV, LLCGAP COINVESTMENTS V, LLCGENERAL ATLANTIC (CIN), L.P.GENERAL ATLANTIC (LUX) S.A R.L.GENERAL ATLANTIC (SPV) GP, LLCGENERAL ATLANTIC GENPAR (BERMUDA), L.P.GENERAL

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D eh220219177_13d-cincor.htm SC 13D 262918
2 EXHIBIT 1 eh220219177_ex01.htm EX-99.1 29595
3 EXHIBIT 3 eh220219177_ex03.htm EX-99.3 32355
  Complete submission text file 0000950142-22-000407.txt   327352
Mailing Address 55 EAST 52ND STREET 33RD FLOOR NEW YORK NY 10055
Business Address 55 EAST 52ND STREET 33RD FLOOR NEW YORK NY 10055 212 715 4000
GENERAL ATLANTIC, L.P. (Filed by) CIK: 0001017645 (see all company filings)

IRS No.: 133503735 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D

Mailing Address 200 CLARENDON STREET, 6TH FLOOR BOSTON MA 02116
Business Address 200 CLARENDON STREET, 6TH FLOOR BOSTON MA 02116 8445311834
CinCor Pharma, Inc. (Subject) CIK: 0001868734 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-93228 | Film No.: 22545170
SIC: 2834 Pharmaceutical Preparations